Log in or Sign up for Free to view tailored content for your specialty!
Neurocritical Care News
Physical exercise prevents nerve damage caused by chemotherapy
Certain physical exercises may prevent nerve damage caused by chemotherapy among individuals being treated for cancer, results of a randomized study published in JAMA Internal Medicine showed.
Tissue bridges linked with short, long-term benefits in those with spinal cord injury
Implementation of tissue bridges measured within the first weeks after spinal cord injury are linked with short-and-long-term clinical improvement, according to research from The Lancet Neurology.
Log in or Sign up for Free to view tailored content for your specialty!
Monoclonal antibody for FSHD improves muscle strength with no serious adverse events
Avidity Biosciences Inc. has announced positive data from the phase 1/2 FORTITUDE clinical trial of a proprietary monoclonal antibody that binds to the transferrin receptor 1 conjugated with a siRNA targeting DUX4 mRNA.
VIDEO: Antibiotics linked to exacerbation of myasthenia gravis
DENVER — The use of several common antibiotics led to exacerbation of myasthenia gravis in a small cohort of patients, Sanem P. Uysal, MD, said in this Healio video from the American Academy of Neurology annual meeting.
Results positive in study of antisense oligonucleotide for Huntington’s disease
Wave Life Sciences has announced positive results from its phase 1b/2a clinical trial of WVE-003, a potential disease-modifying therapeutic for Huntington’s disease.
European Commission authorizes subcutaneous Ocrevus for multiple sclerosis
The European Commission has authorized a subcutaneous injection of Ocrevus to treat relapsing multiple sclerosis as well as primary progressive MS, according to the manufacturer.
FDA expands approval of Elevidys to children aged 4 years and older with DMD gene mutation
The FDA has announced approval of a label expansion for Elevidys to include patients with Duchenne muscular dystrophy aged 4 years and older with a confirmed mutation in the DMD gene.
FDA approves Vyvgart for chronic inflammatory demyelinating polyneuropathy
The FDA has approved Vyvgart Hytrulo in a once-weekly, 30- to 90-second subcutaneous injection to treat adults with chronic inflammatory demyelinating polyneuropathy, according to the manufacturer.
FDA grants Regenerative Medicine Advanced Therapy designation to epilepsy treatment
The FDA has granted Regenerative Medicine Advanced Therapy designation to a novel regenerative cell therapy to treat drug-resistant mesial temporal lobe epilepsy, according to the manufacturer.
FDA approves generic Emflaza for children with Duchenne muscular dystrophy
The FDA has approved an abbreviated new drug application for a generic version of Emflaza to treat Duchenne muscular dystrophy, according to the manufacturer.
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read